Regeneron says antibody cocktail reduces risk of contracting Covid by 80% for at least 8 MONTHS  


BREAKING NEWS: Regeneron says its antibody cocktail reduces the risk of contracting Covid by more than 80% for at least EIGHT MONTHS

  • Regeneron say its antibody cocktail REGEN-COV reduces the risk of contracting COVID-19 by 81.6% two to eight months after it is administered 
  • The drug was authorized last year as a treatment for the virus but has since been expanded so it can be used as a prophylactic  


Regeneron Pharmaceuticals Inc announced on Monday that its antibody cocktail can severely slash the risk of being infected with COVID-19 for up to eight months. 

The combo therapy, REGEN-COV, was approved in November 2020 for emergency use to treat people with mild-to-moderate COVID-19 cases in the U.S.

But the U.S. Food and Drug Administration (FDA) expanded authorization in July 2021 so the drug can also be used as a preventive treatment.

Late-stage trial data showed a single dose can lower the risk of contracting Covid by 81.6 percent between two and six-months after the cocktail is administered. 

Regeneron say its antibody cocktail REGEN-COV (above) reduces the risk of contracting COVID-19 by 81.6% two to eight months after it is administered

Regeneron say its antibody cocktail REGEN-COV (above) reduces the risk of contracting COVID-19 by 81.6% two to eight months after it is administered 

‘Today’s new data demonstrate how a single dose of REGEN-COV can help protect people from COVID-19 for many months after administration,’ Dr Myron S. Cohen, who leads the monoclonal antibody efforts for the COVID Prevention Network sponsored by the National Institutes of Health, said in a statement.

‘These results demonstrate that REGEN-COV has the potential to provide long-lasting immunity from SARS-CoV-2 infection, a result particularly important to those who do not respond to COVID-19 vaccines including people who are immunocompromised.’ 

The antibody cocktail, REGEN-COV, is a combination of two drugs: casirivimab and imdevimab.

Both are monoclonal antibodies – laboratory-made proteins that mimic the immune system – that target the the spike protein, which the virus uses to enter and infect cells.

These cocktails deliver virus-fighting antibodies into the body unlike traditional vaccines in which the receiver’s immune system is activated to develop its own antibodies.

This is a breaking news story and will be updated.

Advertisement

Leave a Reply

Your email address will not be published.